NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
25.50
+0.04 (0.16%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease.
It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
NewAmsterdam Pharma Company N.V.
| Country | Netherlands |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Michael Davidson |
Contact Details
Address: Gooimeer 2-35 Naarden, 1411 DC Netherlands | |
| Phone | 31 35 206 2971 |
| Website | newamsterdampharma.com |
Stock Details
| Ticker Symbol | NAMS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001936258 |
| ISIN Number | NL00150012L7 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael Harvey Davidson FACC, Facp., M.D. | Chief Executive Officer, President, Executive Board Member and Director |
| Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board and Director |
| Mayur Amrat Somaiya | Chief Financial Officer |
| Juliette Audet M.B.A., M.Sc. | Chief Business Officer |
| Douglas F. Kling | Chief Operating Officer |
| Louise Kooij | Chief Accounting Officer |
| Matthew Philippe | Executive Vice President &Head of Investor Relations |
| Bob Rambo | Executive Vice President of Marketing |
| Dr. Marc Ditmarsch M.D. | Chief Development Officer |
| Dr. Sheng Cui Ph.D. | Chief Manufacturing Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Dec 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Dec 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Dec 13, 2024 | 8-K | Current Report |
| Dec 13, 2024 | 424B5 | Filing |
| Dec 11, 2024 | S-3MEF | Filing |
| Dec 10, 2024 | 424B5 | Filing |
| Dec 10, 2024 | 8-K | Current Report |
| Dec 10, 2024 | 8-K | Current Report |
| Nov 20, 2024 | 8-K | Current Report |